Page last checked
Growth hormone-releasing factor analogue (research compound) · dosing
CJC-1295 dosage: the reported range, and what it rests on
People report taking CJC-1295 at 1–2 mg a week, split over one or two injections of the drug-affinity-complex version. That range is what circulates, not what a study found. Human studies of CJC-1295 do exist, and they used other quantities — those are further down this page. None of them produced this range. Nothing here is a starting point, a schedule, or a recommendation.
Source: Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol 2026 — tabulates self-reported online dosing patterns beside the clinical doses, stating the reported values must not be read as clinically validated, regulatory-approved or safe
What matters first
What people report using, and what each figure rests on
Every published CJC-1295 quantity we found, in one table. The last column is the one that matters: it says what produced the number. The rows do not carry equal weight, and the table is built so you can see which is which without being told.
| Quantity | How often | Route | Where the figure came from |
|---|---|---|---|
| 30–60 mcg | per kilogram of body weight — the two of four rising single-dose levels the authors singled out as safe and relatively easy for healthy adults aged 21 to 61 to handle, using the version carrying the drug-affinity complex | Under the skin | A trial in people |
| 60–90 mcg | per kilogram of body weight, as a single injection, with growth hormone sampled overnight a week later in healthy men aged 20 to 40 | Under the skin | A trial in people |
| 1–2 mg | a week, split over one or two injections of the drug-affinity-complex version | Under the skin | Reported use only |
Every row cites a source listed at the foot of this page. A row marked as reported is a description of what people do. It is not evidence that the quantity works, and it is not a dose this site suggests.
Where the CJC-1295 number came from
A range that circulates has a history, and the history is the part sellers leave out. This is what the source behind the row above actually says about its own figure.
The trials gave a single per-kilogram injection and then watched it for nine days, and nothing has tested a milligram quantity repeated weekly
- Every published quantity is per kilogram of body weight. No vial arithmetic follows from it without a weight
One product name covers two substances here, and the difference is not cosmetic.
With the affinity complex the peptide lasts days; without it, minutes. So a protocol, a quantity or a risk written for one does not describe the other. Buyers routinely cannot tell which they hold.
The company that created the long-acting form dropped it, leaving no sponsor, no investigational filing and no pharmacopeial standard for either version.
What this does and does not establish
For CJC-1295, this is the strongest evidence available. The two boxes separate what it can show from what it cannot show.
What it does establish
It shows that people have received it and that some human information exists.
What it does not
It does not prove that the same dose is appropriate in the United States or that uncommon and long-term risks are known.
Check the country, study size and reason it was used. Do not treat limited human data as an FDA-approved schedule.
CJC-1295 dosage in units: 1–2 mg on a syringe
A range in milligrams is not what anyone measures. Below is the same range as a volume and a unit count. Each available vial and water combination has its own row, so match the numbers to the vial in hand. The arithmetic is fixed. The reported range is not a prescription.
| Vial + water | Concentration | Volume | Draw on a U-100 syringe | Doses in the vial |
|---|---|---|---|---|
| 5 mg + 2 mL | 2.5 mg/mL | 0.4–0.8 mL | 40–80 units | 5 |
The vial sizes and water volumes are the CJC-1295 record’s own. The last column counts whole doses at the low end of the range. Every figure here is division applied to a quantity nobody has tested. The arithmetic being exact does not make the quantity right.
3Reference details
Which syringe barrel the units are read on
A unit is not a unit. A U-100 and a U-50 barrel both print 0.01 mL per graduation; a U-40 barrel prints 0.025 mL. The same printed number therefore measures 2.5× the volume on a U-40. That is why every unit figure on this page names its barrel. It is also why a unit count copied from someone else’s syringe means nothing on its own.
| Barrel | Capacity | One graduation | 0.4 mL reads as |
|---|---|---|---|
| U-100 insulin syringe · 1 mL · lines every 2 units | 1 mL | 0.010 mL | 40 units |
| U-100 insulin syringe · 0.5 mL · lines every 1 unit | 0.5 mL | 0.010 mL | 40 units |
| U-40 insulin syringe · 1 mL · lines every 1 unit | 1 mL | 0.025 mL | 16 units |
Barrel capacities and graduation spacing are the printed scales this site’s calculator measures against, not estimates. Three barrels carry only two scales: a U-50 is a half-length U-100, so it reads identically per unit and simply runs out sooner.
What one graduation is worth at each concentration
Reconstitution fixes a concentration, and the concentration fixes what a single graduation carries — before anyone decides what to draw. Below is every pairing of this page’s vial sizes and water volumes, as a concentration and as the mass one U-100 graduation holds at it. No dose is implied by any cell; it is division.
| Vial | + 2 mL water | + 3 mL water |
|---|---|---|
| 5 mg | 2.5 mg/mL25 mcg per unit | 1.67 mg/mL16.7 mcg per unit |
Vial strengths and water volumes are the CJC-1295 record’s own presets. One U-100 graduation is 0.01 mL, so the mass it carries is the concentration times that volume. That is the entire reason the same milligram figure produces a different unit count in every row.
How dosing works in this class
What a reported range is, and what it is not
A reported range tells you what some people say they use. It is not a dose that a human study found safe or effective, and it is not an approved schedule.
We include the range because readers will see the same numbers elsewhere. Here, the source and the type of evidence sit beside it so you can tell a reported amount from a studied dose.
Seeing the same number on several websites does not make it stronger evidence. Those sites may be repeating one source. Do not treat a reported range as a starting dose.
How these figures usually got their shape
Most reported ranges start in an animal study. The dose there is set per kilogram of body weight, so somebody divides and multiplies it up to a person. That step is arithmetic, and it is often done without the scaling method the field uses for it.
The arithmetic travels. The biology does not. How much a body absorbs, where it goes, how fast it clears and how the receptor answers all change between a mouse and a person. None of that is carried across by multiplying.
So a converted figure is a plausible place to start a study. It is not a result.
The other common origin is a round number. Vials are sold in whole milligrams. Quantities that divide a vial neatly spread faster than quantities that do not. That is a fact about packaging, not about the compound.
Concentration changes the units, not the dose
The dose and the syringe draw are two different things. The dose is a mass in milligrams. The draw is a volume in syringe units. It depends on the concentration after mixing. Adding more bacteriostatic water changes the unit reading, but not the dose.
This matters because a unit count copied from someone else’s vial means nothing without their concentration. That mismatch is the most common way a self-injected dose ends up ten times off. The arithmetic is fixed and safe to state as fact. The dose you apply it to is a clinical decision, and it is not.
Compounded vial?
No approved CJC-1295 product exists, so nothing here describes one. The calculator does arithmetic only: it converts a milligram figure and a reconstitution into a volume and a unit count, and it takes no position on which figure belongs in the box.
Open the CJC-1295 calculator →Questions about CJC-1295 dosing
What CJC-1295 dosage do people report using?
The range documented on this page is 1–2 mg a week, split over one or two injections of the drug-affinity-complex version. It describes reported use, not a dose established by a label or a controlled human trial, and it is not a starting point or recommendation.
Has a CJC-1295 dosage been established in a human trial?
Human studies used the separate quantities listed in the evidence table above. None established the reported 1–2 mg range as a schedule, effective dose, or maximum.
How many syringe units is the reported CJC-1295 range?
There is no unit answer without a concentration and a syringe scale. The worked draw table above converts the range only at the stated vial-and-water combinations; a different mix produces a different unit count for the same mass.
Does adding more water change the CJC-1295 dose?
No. It changes the concentration and therefore the volume and syringe units needed to draw a given mass. The milligram or microgram amount does not change merely because the vial contains more water.
Why is there no CJC-1295 dosage chart?
A chart would imply a sourced schedule. CJC-1295 has no approved label that sets one, and the reported range on this page did not come from a controlled human trial. The page therefore reports the range and its provenance without turning it into a ladder to follow.
Where to go next on CJC-1295
CJC-1295 side effects, as the sources describe them
Tesamorelin vs cjc-1295, with the CJC-1295 page in full
What backs the CJC-1295 numbers, and what backs the rest
Mixing math for any vial, not just CJC-1295
Primary regulatory documents, including CJC-1295
Where CJC-1295 sits among the source-checked pages
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91(3):799-805retrieved 2026-08-12Human trial
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91(12):4792-7retrieved 2026-08-12Human trial
- Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol 2026 — tabulates self-reported online dosing patterns beside the clinical doses, stating the reported values must not be read as clinically validated, regulatory-approved or saferetrieved 2026-08-12indirect evidence